Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Extends UDI Deadlines For Low-Risk Devices

Executive Summary

The agency slowed down its effort to require the overwhelming majority of medical devices to adopt Unique Device Identifiers with a new guidance that would in delay full implementation of the UDI system for lower-risk devices.

You may also be interested in...



US FDA Tweaks Direct Marking Rules In UDI Enforcement Delay

FDA’s latest update to Unique Device Identification compliance deadlines says the agency won’t enforce direct marking UDI rules for some existing devices if the UDI can be determined in other ways.

UDI Requirements Come to Brazil

A new regulation from Brazilian device regulator ANVISA will require some high-risk devices to carry Unique Device Identifiers. The rule, which will come into effect in 2020, is the first time the country has mandated UDIs.

Exec Chat: M Holland's Josh Blackmore On Plastics' Hard Impact On Medtech Innovation

Josh Blackmore recently joined M Holland Co., a leading distributor of thermoplastic resin, as its global healthcare manager to help expand the company's participation in the medical device industry. He provides insight on the importance of plastics and how this material plays an important role in helping to drive medical device-makers innovate.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT122052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel